Evofem Biosciences Cash on Hand 2013-2022 | EVFM

Evofem Biosciences cash on hand from 2013 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Evofem Biosciences Annual Cash on Hand
(Millions of US $)
2021 $13
2020 $71
2019 $24
2018 $2
2017 $2
2016 $11
2015 $38
2014 $76
2013 $4
2012 $11
Evofem Biosciences Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $7
2021-12-31 $13
2021-09-30 $24
2021-06-30 $62
2021-03-31 $64
2020-12-31 $71
2020-09-30 $87
2020-06-30 $124
2020-03-31 $11
2019-12-31 $24
2019-09-30 $36
2019-06-30 $51
2019-03-31 $1
2018-12-31 $2
2018-09-30 $13
2018-06-30 $23
2018-03-31 $6
2017-12-31 $2
2017-09-30 $6
2017-06-30 $8
2017-03-31 $10
2016-12-31 $11
2016-09-30 $14
2016-06-30 $21
2016-03-31 $24
2015-12-31 $38
2015-09-30 $51
2015-06-30 $63
2015-03-31 $71
2014-12-31 $76
2014-09-30
2014-06-30
2014-03-31
2013-12-31 $4
2012-12-31 $11
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.005B $0.008B
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00